AIM Vaccine Co., Ltd.
艾美疫苗股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 06660)

VOLUNTARY ANNOUNCEMENT SUBMISSION OF THE APPLICATION FOR MARKETING REGISTRATION OF THE ITERATIVE PROCESS HIGH-POTENCY HUMAN DIPLOID CELL RABIES VACCINE

This announcement is made by AIM Vaccine Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business developments of the Group.

The application for marketing registration of the iterative process high-potency human diploid cell rabies vaccine independently developed by the Company has recently been submitted to the National Medical Products Administration.

According to the results of the Phase III clinical trial, for which unblinding has been completed, the vaccine has good safety, immunogenicity and immune persistence. Its immunogenicity and immune persistence are superior to those of a comparator vaccine of the same type, and all indicators have fully met the pre-defined evaluation criteria of the clinical trial.

This product, as an iterative upgraded human diploid cell rabies vaccine, is characterized by its ultra-high potency, and also marks a major iterative upgrade in the global field of rabies vaccine technology.

Rabies is the disease with the highest fatality rate in the world; once the disease occurs, the fatality rate is nearly 100%. Currently, there is a lack of effective treatment for rabies in clinical practice, therefore, post-exposure prophylaxis is crucial, and the main preventive measure is vaccination with rabies vaccines for human use. Compared with traditional Vero cell rabies vaccines, human diploid cell rabies vaccines use human diploid cells, which are homologous to humans, instead of Vero cells, thereby offering inherent safety advantages. The human diploid cell rabies vaccine currently available in the market is 3 to 5 times more expensive than the Vero cell rabies vaccine, with higher product added value.

Compared with the traditional human diploid cell rabies vaccines of the first generation, the iterative process high-potency human diploid cell rabies vaccine developed by the Group has taken the lead in breaking through the technical bottlenecks of low virus titer and low yield in the traditional process, with optimization and innovation in the purification process, resulting in significant improvements in both product quality and safety. This is not only a manifestation of the Company's R&D strength, but also a major breakthrough in the field of high-potency processes for rabies vaccines globally.

China is the largest rabies vaccine market globally. According to China Insights Consultancy, driven by product upgrades and iterations and the increasing penetration of rabies vaccines, the market is projected to reach RMB14.8 billion in 2030. Compared with traditional rabies vaccination regimens, this product developed by the Group can be administered using either the "five-needle approach", the "simple four-needle approach" or the "2-1-1 four-needle approach", which is more flexible and convenient. In accordance with the Rabies Exposure Prophylaxis Standard (2023 Edition) (《狂犬病暴露預防處置工作規範》(2023年版)) issued by the National Disease Control and Prevention Administration and the National Health Commission, rabies vaccination clinics are required to be equipped with at least two different types of rabies vaccines. By virtue of its iterative technological advantages and flexible vaccination regimens, the Group's product is expected to become the first choice for vaccination institutions. The Group has completed the construction of an iterative process high-potency human diploid cell rabies vaccine workshop that fully meets international standards, and has completed commercial-scale validation production, and possesses the capability for large-scale production of the product.

Human diploid cell rabies vaccine is recommended by the WHO as the gold standard for rabies vaccines, and has been widely applied in many developed countries. As the world's second largest supplier of rabies vaccines, the Group is committed to leading the deep technical iteration and upgrading of rabies vaccines globally, providing the market with a series of rabies vaccine products with better quality and higher safety, further consolidating the Company's leading position in the global rabies vaccine field, and promoting the sustainable development of the Group. In the future, the approval of the product will further enrich the Company's product structure, synergize with its existing rabies vaccine series, and enhance its core competitiveness. As part of its global expansion strategy, the product can contribute additional revenue, strengthen the Company's market position, and add new momentum to the Company's sustained and steady development.

By order of the Board
AIM Vaccine Co., Ltd.
Chairman of the Board and CEO
Mr. Yan ZHOU

Beijing, the PRC, August 24, 2026

As at the date of this announcement, the Board comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Shaojun JIA, Mr. Wen GUAN, Mr. Jie ZHOU and Ms. Ling LIU as executive directors; Mr. Jichen ZHAO as a non-executive director; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Mr. Hui OUYANG and Mr. Weicai SHAO as independent non-executive directors.